Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: Results of an open label, randomized, prospective clinical study

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1791-1797

  Krause, Petra ^a   Fuhr, Uwe ^b   Schnitker, Jörg ^c   Albrecht, Uwe ^d   Stein, Raimund ^e   Rubenwolf, Peter ^e  

^a Itecra GmbH   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Institute of Applied Statistics   (Germany)

^d Mediconomics GmbH   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Adverse effects; Desethyloxybutynin; Oxybutynin; Pharmacokinetics; Urinary bladder

Indexed keywords

OXYBUTYNIN; PARACETAMOL;

ADULT; AGED; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENANTIOSELECTIVITY; FIRST PASS EFFECT; HEMATURIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; OVERACTIVE BLADDER; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VITAL SIGN;

EID: 84888644542     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.011     Document Type: Article

References (24)

1. Franco I, Horowitz M, Grady R et al: Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 2005; 173: 221.
2. Douchamps J, Derenne F, Stockis A et al: The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515.
3. Dmochowski R, Kell S and Staskin D: Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Expert Opin Pharmacother 2002; 3: 443.
4. Mizushima H, Kinoshita K, Abe K et al: Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. Biol Pharm Bull 2007; 30: 955.
5. Yarker YE, Goa KL and Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243.
6. Hughes KM, Lang JC, Lazare R et al: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859.
7. Gupta SK and Sathyan G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39: 289.
8. McCrery RJ and Appell RA: Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag 2006; 2: 19.
9. Zobrist RH, Schmid B, Feick A et al: Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001; 18: 1029.
10. Noronha-Blob L and Kachur JF: Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 1991; 256: 562.
11. Kachur JF, Peterson JS, Carter JP et al: R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 1988; 247: 867.
12. Buyse G, Verpoorten C, Vereecken R et al: Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 1998; 160: 1084.
13. Amark P, Bussman G and Eksborg S: Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998; 34: 148.
14. Greenfield SP and Fera M: The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 1991; 146: 532.
15. Massad CA, Kogan BA and Trigo-Rocha FE: The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992; 148: 595.
16. Weese DL, Roskamp DA, Leach GE et al: Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993; 41: 527.
17. Lehtoranta K, Tainio H, Lukkari-Lax E et al: Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002; 36: 18.
18. Amark P, Eksborg S, Juneskans O et al: Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. Br J Urol 1998; 82: 859.
19. Madersbacher H and Knoll M: Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results. Eur Urol 1995; 28: 340.
20. Saito M, Tabuchi F, Otsubo K et al: Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn 2000; 19: 683.
21. Buyse G, Waldeck K, Verpoorten C et al: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998; 160: 892.
22. Tapp AJ, Cardozo LD, Versi E et al: The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521.
23. Singh G and Thomas DG: Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators. Neurourol Urodyn 1995; 14: 65.
24. Guerra LA, Moher D, Sampson M et al: Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol 2008; 180: 1091.